Interplay between H6PDH and 11β-HSD1 implicated in the pathogenesis of type 2 diabetes

被引:6
|
作者
Yao, Fan [1 ]
Chen, Li [1 ,2 ]
Fan, Zheng [1 ]
Teng, Fei [1 ]
Zhao, Yali [1 ]
Guan, Fengying [1 ]
Zhang, Ming [1 ]
Liu, Yanjun [3 ]
机构
[1] Jilin Univ, Dept Pharmacol, Coll Basic Med Sci, Changchun 130021, Peoples R China
[2] Jilin Univ, Sch Nursing, Changchun 130021, Peoples R China
[3] Univ Calif Los Angeles, Sch Med, Div Endocrinol Metab & Mol Med, Charles R Drew Univ Med & Sci, Los Angeles, CA USA
基金
中国国家自然科学基金;
关键词
H6PDH; 11; beta-HSD1; Corticosterone; Liver; Type 2 diabetes mellitus; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1; HEXOSE-6-PHOSPHATE DEHYDROGENASE; GLUCOCORTICOID-RECEPTOR; INSULIN-RESISTANCE; DB/DB MICE; EXPRESSION; CONTRIBUTE; OBESITY; HYPERGLYCEMIA; HEPATOCYTES;
D O I
10.1016/j.bmcl.2017.07.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Extensive studies have been performed on the role of 11 beta-hydroxysteroid dehydrogenase 1 (11 beta-HSD1) in metabolic diseases. Our previous study reported glucose could directly regulate hexose-6-phosphate dehydrogenase (H6PDH) and 11 beta-HSD1. Recently, we further investigated the interplay of H6PDH and 11 beta-HSD1 and their roles in hepatic gluconeogenesis and insulin resistance to elucidate the importance of H6PDH and 11 beta-HSD1 in pathogenesis of type 2 diabetes mellitus (T2DM). T2DM rats model and H6PDH or 11 beta-HSD1 siRNA transfected in CBRH-7919 cells were used to explore the effect of H6PDH and 11 beta-HSD1 in T2DM. The results showed that the expression and activity of H6PDH and 11 beta-HSDI in livers of diabetic rats were increased, with the expressions of PEPCK and G6Pase or liver corticosterone increased apparently. It also showed that H6PDH siRNA and 11 beta-HSD1 siRNA could inhibit the protein expression and enzyme activity by each other. With H6PDH siRNA, the enhancement of gluconeogenesis was blocked and insulin resistance stimulated by corticosterone was reduced. H6PDH and 11 beta-HSD1 might be the effective and prospective targets for T2DM and metabolic syndromes, based on the interplay between these two enzymes. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4107 / 4113
页数:7
相关论文
共 50 条
  • [41] Interaction of HSD11B1 and H6PD polymorphisms in subjects with type 2 diabetes are protective factors against obesity: a cross-sectional study
    Marcio F. Chedid
    Filipe V. do Nascimento
    Fernanda S. de Oliveira
    Bianca M. de Souza
    Cleber R. P. Kruel
    Richard R. Gurski
    Luis H. Canani
    Daisy Crispim
    Fernando Gerchman
    Diabetology & Metabolic Syndrome, 11
  • [42] Interaction of HSD11B1 and H6PD polymorphisms in subjects with type 2 diabetes are protective factors against obesity: a cross-sectional study
    Chedid, Marcio F.
    do Nascimento, Filipe V.
    de Oliveira, Fernanda S.
    de Souza, Bianca M.
    Kruel, Cleber R. P.
    Gurski, Richard R.
    Canani, Luis H.
    Crispim, Daisy
    Gerchman, Fernando
    DIABETOLOGY & METABOLIC SYNDROME, 2019, 11 (01):
  • [43] Memory deficits in a juvenile rat model of type 1 diabetes are due to excess 11β-HSD1 activity, which is upregulated by high glucose concentrations rather than insulin deficiency
    Julie Brossaud
    Clémentine Bosch-Bouju
    Nathalie Marissal-Arvy
    Marie-Neige Campas-Lebecque
    Jean-Christophe Helbling
    Scott P. Webster
    Brian R. Walker
    Xavier Fioramonti
    Guillaume Ferreira
    Pascal Barat
    Jean-Benoît Corcuff
    Marie-Pierre Moisan
    Diabetologia, 2023, 66 : 1735 - 1747
  • [44] Memory deficits in a juvenile rat model of type 1 diabetes are due to excess 11β-HSD1 activity, which is upregulated by high glucose concentrations rather than insulin deficiency
    Brossaud, Julie
    Bosch-Bouju, Clementine
    Marissal-Arvy, Nathalie
    Campas-Lebecque, Marie-Neige
    Helbling, Jean-Christophe
    Webster, Scott P.
    Walker, Brian R.
    Fioramonti, Xavier
    Ferreira, Guillaume
    Barat, Pascal
    Corcuff, Jean-Benoit
    Moisan, Marie-Pierre
    DIABETOLOGIA, 2023, 66 (09) : 1735 - 1747
  • [45] The Interplay between Polygenic and Rare HNF1A Variant Risk in Type 2 Diabetes
    Stalbow, Lauren
    Preuss, Michael H.
    Chami, Nathalie
    Smit, Roelof A. J.
    Loos, Ruth J.
    DIABETES, 2022, 71
  • [46] Association of HSD11B1 gene polymorphisms with type 2 diabetes and metabolic syndrome in South Indian population
    Devang, Nayana
    Satyamoorthy, Kapaettu
    Rai, Padmalatha S.
    Nandini, M.
    Rao, Satish
    Phani, Nagaraja M.
    Adhikari, Prabha
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 131 : 142 - 148
  • [47] Synthesis and Docking Studies of the Novel N-(2,2-Di(1H-pyrrol-2-yl) ethyl) adamantane-1-carboxamide, a Potential 11β-HSD1 Inhibitor
    Gallardo-Alfonzo, Salvador
    Lilia Ocampo-Nestor, Ana
    Contreras-Celedon, Claudia
    Chacon-Garcia, Luis
    JOURNAL OF CHEMISTRY, 2014, 2014
  • [48] MEDI 257-Discovery of hydroxyisoquinolines as novel and potent 11-β-HSD-1 inhibitors for the treatment of type 2 diabetes
    Wu, Shung C.
    Yoon, David S.
    Van Kirk, Katy
    Padmanabha, Ramesh
    Cook, Lynda S.
    Nayeem, Akbar
    Gordon, David
    Seethala, Ramakrishna
    Golla, Rajasree
    Hosagrahara, Vinayak
    Zhang, Lisa
    Wang, Meng Meng
    Sleczka, Bogdan
    Harper, Timothy
    Harrity, Thomas
    Taylor, Joseph
    Poticello, Randolph
    Zebo, Rachel
    Morgan, Nathan
    Kirby, Mark S.
    Bin, He
    Knox, Ronald J.
    Zvyaga, Tatyana
    Shou, Wilson
    Li, Yi-Xin
    Robl, Jeffery A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2008, 236
  • [49] HSD11B1 gene polymorphisms in type 2 diabetes and metabolic syndrome—Do we have evidence for the association?
    Nayana Devang
    Nandini M
    Satish Rao
    Prabha Adhikari
    International Journal of Diabetes in Developing Countries, 2016, 36 : 95 - 102
  • [50] Metabolic effects and safety of two selective 11β-HSD1 inhibitors (RO5093151 (RO151) and RO5027838 (RO838) in metformin- treated patients with type 2 diabetes
    Fuerst-Recktenwald, S.
    Heise, T.
    Hompesch, M.
    Pieber, T.
    Haering, H. -U.
    Kapitza, C.
    Abt, M.
    Ramsauer, M.
    Morrow, L.
    DIABETOLOGIA, 2013, 56 : S407 - S408